Cardiac Amyloidosis Treatment.

Introduction

Cardiac amyloidosis (CA) is a rare and progressive disease resulting from protein buildup in cardiac muscle. Treatment options for CA were previously limited to symptom management. Over the last decade, however, there have been significant advances in disease-modifying therapies that provide hope for slowing disease progression to optimize quality of life and improve survival. Here we provide an overview of novel and experimental treatment strategies for the predominant types of CA, transthyretin cardiac amyloidosis (ATTR-CA) and immunoglobulin light chain (AL)-mediated CA, or AL-CA ( Figure 1 , Table 1 ). 1 , 2

Disease-Modifying Treatment for AL Cardiac Amyloidosis

AL-CA results from misfolded immunoglobulin light-chain proteins that infiltrate cardiac muscle and lead to organ failure. Since extent of light chain fibril deposition and resultant toxicity drives AL-CA disease severity and prognosis, the aim of treatment is to eradicate the underlying plasma cell clone that produces the excess light chains. Chemotherapy regimens and autologous stem cell transplantation (ASCT) have been adapted from treatment of multiple myeloma, a related plasma cell dyscrasia. While treatment is directed by the hematologist-oncologist, many regimens have significant toxicities that are poorly tolerated in patients with cardiac involvement, so it is critical to have a close alignment with the cardiologist on the treatment team.

The goal of treatment is to administer the strongest chemotherapy regimen that the patient can safely tolerate with the intent of improving organ function and survival. 3 , 4 Even in advanced cardiac disease (Mayo cardiac stage IIIb), early response at 1 month has been associated with improved overall survival. 5 Success is determined by hematologic response (suppression of serum free light chains) and organ-specific response (evaluation of cardiac and renal biomarkers). A recently validated composite hematologic/organ response model 6 classifies patients into two treatment response groups to determine early clinical benefit, and it has shown a higher prognostic power than assessment of isolated hematologic or organ response. Rapid improvement in left ventricular (LV) thickness and function is uncommon after treatment regardless of improvement in cardiac biomarkers. Global longitudinal strain and cardiac magnetic resonance imaging with T1 mapping and extracellular volume measurements provide more subtle evidence of structural treatment response. 7 , 8

Up-Front Amyloidosis Therapy

Risk stratification dictates initial treatment strategy for AL-CA patients. High-dose melphalan with ASCT provides the greatest opportunity for long-term remission. However, to qualify for ASCT as initial therapy, patients must be low risk, defined as age < 70 years old with good functional status (Eastern Cooperative Oncology Group performance status [ECOG PS] < 2) and without significant organ dysfunction, including New York Heart Association (NYHA) class < III and biomarker levels below validated thresholds. Due to disease severity and comorbidities at the time of diagnosis, less than one in five patients are eligible for up-front ASCT. If there is high bone marrow plasma cell infiltration (> 10%) and/or any anticipated delay in initiation of ASCT, patients may require induction therapy with the proteosome inhibitor bortezomib, with dexamethasone and an alkylating agent. Bortezomib-based induction therapy has been shown to improve progression-free survival with an 84% hematologic response (39% complete response) and an 84% overall 5-year survival. 9 Bortezomib-based therapies are also used after ASCT for consolidation treatment if there is less than a very good partial response.

For intermediate risk (cardiac stage I-IIIa) 10 patients who initially do not qualify for ASCT, chemotherapy is initiated, and ASCT can be reconsidered if reversible contraindications improve. For many years, the standard chemotherapy regimen was high-dose melphalan with dexamethasone, but the addition of bortezomib in recent years has become the standard of care, with significantly improved hematologic response and overall survival in a phase 3 randomized open-label trial. 11 The two most common regimens are cyclophosphamide-bortezomib-dexamethasone (CyBorD) and bortezomib-melphalan-dexamethasone. Recently, the anti-CD38 human IgG-κ monoclonal antibody, daratumumab, previously used for relapsed or refractory AL, has also become part of the standard up-front regimen. The ANDROMEDA phase 3 trial showed that subcutaneously administered daratumumab plus CyBorD compared with CyBorD alone had more rapid and significant hematologic response (53% vs 18%) and improved survival from major organ deterioration or hematologic progression (HR 0.58; CI 0.36-0.93) for newly diagnosed AL. 12 Although there was an overall increase in lymphopenia and severe infections, the incidence of overall severe adverse events was lower in the daratumumab group when adjusted for exposure to trial treatment. Of note, most of the trial population had NYHA class II (40%) and NYHA Class IIIa (34%) symptoms. In a prespecified subgroup analysis, daratumumab demonstrated an escalating hematologic response with higher NYHA class, suggesting particular efficacy and safety for those with higher-grade cardiac involvement. After the ANDROMEDA trial, daratumumab with hyaluronidase-fihj became the first FDA-approved treatment for AL amyloidosis. 13

High-risk patients with poor functional capacity (ECOG PS 4) and advanced cardiac involvement (NYHA class IIIb or IV) often do not tolerate standard chemotherapy and may require reduced doses or a sequential introduction of chemotherapy agents with frequent reassessment for potential aggressive escalation. Given the increasing evidence for daratumumab in this population, monotherapy daratumumab is being investigated for newly diagnosed stage IIIb AL in a phase 2 open-label trial. 14

Contraindications to bortezomib include pulmonary fibrosis and peripheral neuropathy. Carfilzomib is another second-generation proteasome inhibitor that is beneficial in place of bortezomib for those with significant neuropathy; however, it is associated with a rise in NT-proBNP and cardiotoxicity and therefore not used for those with AL-CA. 15 Additional consideration for regimen selection is the presence of genetic abnormalities. The chromosomal translocation 11; 14 is present in up to 60% of AL cases and is associated with poorer outcomes with bortezomib and immunomodulatory therapy (IMiD), whereas the gain of function 1(q21) has been associated with poorer response to melphalan. Alternative therapies for patients with contraindications to bortezomib are under investigation, including the oral selective B-cell lymphoma 2 inhibitor, venetoclax, for patients with t(11;14), although limited data are available. 16

Refractory or Relapsed AL Therapy

Patients who relapse or are refractory to up-front therapy are usually treated with daratumumab, if not already initiated, based on many promising retrospective and phase 2 trials. 17 , 18 Otherwise, IMiD and low-dose dexamethasone with or without cyclophosphamide are used. The IMiDs lenalidomide, pomalidomide, and thalidomide have shown efficacy in retrospective and phase 2 clinical trials but have not been compared to other regimens. 19 Lenalidomide and thalidomide treatment have been associated with thrombotic complications requiring thromboprophylaxis. IMiDs have been associated with a discordant rise in NT-proBNP levels despite improvement in free light chains, which poses challenges for cardiac response assessment. 20 An all-oral regimen for relapsed or refractory AL with the proteasome inhibitor ixazomib plus dexamethasone was studied in the TOURMALINE-AL1 phase 3 study; while not associated with improved overall hematologic response, it demonstrated a higher complete response rate (26% vs 18%) and longer progression-free survival compared with physicians’ choice (47% lenalidomide plus dexamethasone). 21 A non-IMiD–based rescue regimen with the alkylating agent bendamustine and dexamethasone has also been investigated in a phase 2 study and demonstrated a 57% hematologic response rate.

Immunotherapy with monoclonal antibody NEOD001 has also been investigated. However, the PRONTO phase 2b trial for AL-CA with refractory cardiac dysfunction failed to meet primary and secondary end points, and the VITAL phase 3 trial for treatment-naive AL-CA was discontinued based on futility analysis. 22 Another chimeric monoclonal antibody, CAEL-101, which targets AL amyloid deposits, was found to be well tolerated in a phase 2 study 23 and is now under investigation in two phase 3 trials in Mayo Stage IIIa 24 and Stage IIIb 24 , 25 disease.

Adjunct AL Therapy

Epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea, is a major antioxidant that has been shown to stabilize misfolded amyloid fibrils into a less toxic form and prevent formation of insoluble amyloid fibrils. 26 EGCG has been investigated in three phase 2 trials for treatment of AL-CA. Two of these trials have completed enrollment—EpiCardiAL 27 and TAME-AL—but results had not been published at time of publication. 28 A small single-center Japanese study of 57 patients did not report a significant benefit for use of EGCG but also did not report any significant toxicity. 29 Because EGCG is well tolerated, it is often added as an adjunct to AL-CA treatment regimens.

The antibiotic doxycycline has been shown to disrupt AL amyloid fibril formation in transgenic mice and to counteract AL amyloid toxicity in C elegans. 30 , 31 It showed promise in retrospective studies to improve hematologic response and overall survival. 32 , 33 However, a recent prospective trial of 140 patients randomized to CyBorD with doxycycline showed no benefit for hematologic or cardiac progression-free survival, so the role of doxycycline has become less clear. 34 We await results of an ongoing randomized control trial investigating the addition of doxycycline to bortezomib-based therapy. 35

Disease-Modifying Treatment of ATTR Cardiac Amyloidosis

Until recently, treatment of ATTR-CA was aimed at management of symptoms and disease-related complications. However, novel and experimental therapies for treatment of ATTR-CA wild-type (ATTRwt-CA) and hereditary/variant (ATTRv-CA) are emerging. Strategies for disease-modifying therapies target various steps along the ATTR-CA amyloid production process, including gene silencing to prevent hepatocyte TTR production, TTR stabilization to prevent TTR tetramer dissociation, anti-TTR antibodies, inhibition of TTR oligomer aggregation, and degradation of deposited ATTR fibrils with the goal to reverse the disease process, restore cardiac function, and consequently improve morbidity and mortality.

ATTR Silencers

Two gene silencer therapies, patisiran and inotersen, are FDA approved for ATTRv polyneuropathy based on multicenter, international, randomized controlled phase 3 trials. Findings from cardiac subgroup analyses have prompted investigation for utility in ATTRv-CA and ATTRwt-CA.

Patisiran is a small interfering RNA that binds to the RNA-induced silencing complex and mediates cleavage of the transthyretin mRNA to prevent formation of TTR. It is administered intravenously every 3 weeks. The APOLLO randomized controlled trial evaluated the effect of patisiran for treatment of 225 patients with ATTRv polyneuropathy, 126 (56%) of whom had concomitant cardiac involvement. 36 In addition to demonstrating slower progression of polyneuropathy at 18-months, a prespecified ATTRv-CA subgroup demonstrated improvement in NT-proBNP levels as well as echocardiographic parameters, including cardiac output, LV wall thickness, end-diastolic volume, and global longitudinal strain. 37 The sub-study also demonstrated improved functional capacity (10-meter walk test) as well as decreased hospitalization and mortality with patisiran compared to placebo at 18-months. These results prompted the APOLLO-B phase 3 randomized controlled trial, 38 which has completed enrollment with results pending, to evaluate patisiran for ATTRv-CA and ATTRwt-CA with the primary end point of 6-minute walk test (6MWT) performance and secondary end points of death and hospitalization at 12 months.

Inotersen is an antisense oligonucleotide inhibitor of transthyretin mRNA produced by the liver that is administered weekly by subcutaneous injection. The NEURO-TTR randomized controlled trial 39 evaluated inotersen for 172 ATTRv polyneuropathy patients, 105 (61%) with cardiac involvement. Like APOLLO, NEURO-TTR demonstrated slower progression of polyneuropathy and improved quality of life; unlike APOLLO, there was no significant improvement in echocardiographic parameters within the prespecified cardiac subgroup. However, in an interim analysis of inotersen in a single-center open-label study, 40 33 patients with biopsy proven ATTR-CA without polyneuropathy (10 ATTRv-CA and 23 ATTRwt-CA) but with NYHA class I-III symptoms demonstrated a decrease in LV mass and improved exercise tolerance in 6MWT by 2 and 3 years of follow-up. A separate 24-month, single-center, open-label study of 50 patients with ATTRwt-CA or ATTRv-CA is ongoing. 41

Although the subcutaneous use of inotersen may be preferable to the intravenously administered patisiran, post-hoc comparison of the APOLLO and NEURO-TTR trials demonstrates more improved neuropathy symptoms and a lower risk of adverse effects for patisiran compared with inotersen. NEURO-TTR demonstrated a higher frequency of serious adverse events with inotersen compared to placebo (32% vs 22%,), including thrombocytopenia and glomerulonephritis. In contrast, patisiran compared favorably with placebo in the APOLLO study. Patients in the patisiran group were premedicated with dexamethasone, acetaminophen, an H2-blocker, and an H1-blocker, which may have decreased adverse reactions.

From an historical perspective, it is important to note that a different RNA interference agent, revusiran, was evaluated for ATTRv-CA in the ENDEAVOUR phase 3 trial, 42 which was prematurely terminated at 6 months due to increased mortality compared with placebo (14% vs 3%). Most deaths were determined to be due to heart failure, and a post-hoc safety investigation failed to reveal a causative mechanism.

Other ongoing randomized controlled trials include two novel silencer treatments for ATTR-CA (ATTRv-CA and ATTRwt-CA): vutrisiran and eplontersen. The HELIOS-B study 43 is evaluating vutrisiran, another RNA interference therapy, with a primary composite end point of all-cause mortality and recurrent hospitalizations at 30 months. Like inotersen, vutrisiran is administered subcutaneously but with the advantage of dosing every 3 months rather than weekly. The CARDIO-TTRansform study 44 is evaluating eplontersen, a ligand conjugated antisense oligonucleotide, for a primary end point of cardiovascular mortality and clinical events at 120 weeks. Eplontersen is administered every 4 weeks with an improved formulation targeting fewer side effects than inotersen.

Another exciting novel method for reduction of hepatocyte TTR production is the CRISPR-Cas9 system (clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease) gene editing treatment, which knocks out the TTR gene. In an open-label, multicenter study, intravenous injection of NTLA-2001 by the CRISPR-Cas9 method in six patients with ATTRv polyneuropathy was demonstrated to reduce serum concentrations of TTR by up to 87% by 4 weeks, with only mild adverse events in 3 patients. 45 It is hoped that this one-time therapy provides durable knockdown of TTR with subsequent improvement in clinical outcomes. The initial pilot study in a small cohort suggests that treatment is safe and well tolerated with no signal for off-target gene editing. This is one of the first clinical applications for this gene editing technology, which appears particularly suited for ATTR because the protein is predominantly synthesized in the liver, and the CRISPR-Cas9 system can target the liver by encapsulation in a lipid nanoparticle with avidity for the low-density lipoprotein (LDL) receptor.

ATTR Stabilizers

Diflunisal is a nonsteroidal anti-inflammatory (NSAID) medication that has demonstrated TTR stabilization in vitro 46 but has only been studied in small, nonrandomized, mostly noncomparative single-arm prospective cohort trials of predominantly ATTRv-CA. 47 , 48 , 49 , 50 Although these studies suggest stabilization of cardiac biomarkers and echocardiographic parameters, formal randomized controlled trials are needed to confirm these findings and determine an impact on morbidity and mortality. While diflunisal is generally considered safe and well tolerated, as an NSAID it is contraindicated in patients with significant thrombocytopenia and or renal dysfunction (glomerular filtration rate < 40 mL/min/1.73m 2 ) and can cause gastrointestinal intolerance, bleeding, and heart failure exacerbation.

An analog of diflunisal, tafamadis has TTR stabilization characteristics but is not an NSAID. It is the only FDA-approved medication for both types of ATTR-CA since May 2019 after showing positive results in the ATTR-ACT study (Transthyretin Amyloidosis Cardiomyopathy Clinical Trial). 51 This study evaluated 441 ATTR-CA patients (106 ATTRv-CA and 335 ATTRwt-CA) for treatment with oral tafamidis 80 mg vs tafamidis 20 mg vs placebo. In a pooled analysis, both doses of tafamidis were associated with a reduction in all-cause mortality (29.5% vs 42.9%, HR 0.70; CI 0.51-0.96) and cardiovascular hospitalizations (RR 0.68; CI 0.56-0.81) at 30 months ( Figure 2 ). Secondary end points were notable for a lower rate of functional capacity decline by 6MWT distance and of quality-of-life decline by Kansas City Cardiomyopathy Questionnaire–Overall Summary score. There was a smaller increase in NT-proBNP levels and less worsening of circumferential and radial global strain without effect on other echocardiographic parameters, with no significant safety problems reported. However, there was a higher rate of cardiovascular-related hospitalizations in the patients with NYHA class III symptoms on treatment, which has been postulated to be due to longer survival in a more critical stage of disease. Nevertheless, poorer outcomes in more advanced disease states suggest the importance of early administration to prevent TTR fibril formation and concern for ineffectiveness for disease reversal with this strategy.

With FDA approval and a reassuring safety profile, tafamidis has become a mainstay of treatment for ATTR-CA. Although tafamidis has demonstrated significant efficacy in staving off disease progression, patients require life-long therapy, and the cost for many is prohibitive despite insurance, charity, and drug maker assistance programs. A cost-effectiveness model has indicated that the cost of tafamidis would need to be reduced by > 90% to be cost effective. 52

Acoramidis, formerly known as AG-10, is a novel oral TTR stabilizer that mimics a protective TTR mutation (T119M). In ex vivo studies, acoramidis binds more strongly to TTR than tafamidis. 53 Acoramidis is currently being investigated in the phase 3 randomized controlled trial, ATTRIBUTE-CM, for treatment of ATTR-CA NYHA Class I-III symptoms. 54

Inhibition of Oligomer Aggregation and Disruption

Epigallocatechin-3-gallate has been shown to inhibit TTR amyloid fibril formation in vitro and in vivo in mice, 55 , 56 although there have been only three small noncomparative prospective single-arm studies with follow-up for only 7 to 25 patients with ATTRwt-CA and ATTRv-CA. 57 , 58 , 59 One 14-patient study demonstrated significant reduction in interventricular septal thickness in 12 patients, but it was not reproduced in the other studies. 59 All cohorts demonstrated a very small reduction in LV mass by cardiac magnetic resonance imaging, and one study had a signal for mildly reduced T1 time without reduction in extracellular volume. Nevertheless, as with AL-CA, EGCG is often prescribed due to its benign safety profile.

ATTR Degraders

While many of the other ATTR-CA treatments target interference of amyloid formation and deposition, an amyloid degradation strategy targets already deposited amyloid fibrils and promotes breakdown and clearance. Doxycycline and tauroursodeoxycholic acid (TUDCA) or ursodeoxycholic acid (UDCA) have been shown to remove amyloid deposits in preclinical studies. 60 Only three noncomparative prospective single-arm studies have investigated this combination therapy, and they demonstrated modest results with a high attrition rate (~10%) due to esophageal and dermatologic intolerance from doxycycline. 61 , 62 , 63 However, given the high cost of other disease-modifying therapies, doxycycline with TUDCA/UDCA is a desirable, cheaper option if it is determined to be effective in a phase 3 randomized controlled trial that has completed recruitment, with results pending. 64

ATTR Immunotherapy

Immunotherapy is also being investigated for treatment of ATTR-CA. PRX004 (Prothena) is an intravenously administered anti-TTR humanized monoclonal antibody. In preclinical studies, it was shown to promote clearance of insoluble amyloid fibrils through antibody-mediated phagocytosis and inhibition of amyloid fibril formation. A recent phase I open-label multicenter study was terminated early due to the COVID-19 pandemic; however, analysis of 7 patients with ATTRv-CA (NYHA Class I and II) demonstrated safety, improvement in neuropathic symptoms, and a modest improvement in global longitudinal strain (-1.21%) after 9 months of treatment. 65 Another anti-TTR recombinant human monoclonal antibody, NI006, has also shown high affinity for binding to ATTRv and ATTRwt ex vivo and in vivo. 66 It is currently under investigation for ATTR-CA in a phase 1, randomized, placebo-controlled double-blind trial 67 with plans for a subsequent open-label extension to investigate safety and efficacy. From an historical perspective, it is important to note that the anti-serum amyloid P (SAP) component antibody, GSK2315698, initially garnered excitement for amyloid fibril clearance in a phase 1 trial (excluding those with cardiac involvement). 68 However, due to an adverse risk/benefit profile in a phase 2 trial of ATTR-CA, its development was terminated. 69

General Cardiac Management

In addition to specific disease-modifying therapies, general management of CA focuses on treatment of heart failure symptoms and arrhythmias with the goal of optimizing quality of life. Since CA has traditionally been considered a rare and lethal condition, CA patients have been excluded from heart failure randomized controlled trials, so treatment recommendations have been limited to expert consensus and small cohort studies.

The cornerstone of treatment for CA is loop diuretic therapy. As CA patients have a very narrow window of volume optimization due to small, stiff ventricles with limited stroke volume, they can easily become volume overloaded with resultant pulmonary, hepatic, and renal congestion. Conversely, with slight overdiuresis, an already decreased stroke volume is further reduced, resulting in kidney, brain, and muscle hypoperfusion contributing to renal insufficiency and profound fatigue. Due to frequent gut edema, the more bioavailable loop diuretics, bumetanide and torsemide, are commonly used over furosemide and are sometimes paired with a mineralocorticoid receptor antagonist (MRA) with close monitoring of potassium and renal function. Compression stockings are also used to mobilize edema and to assist with frequent co-occurrence of autonomic dysfunction, particularly with AL-CA and ATTRv-CA. Patients are instructed to limit sodium intake and to closely monitor daily weights and blood pressure since subtle volume changes can have large hemodynamic effects.

There is no established guideline-directed medical therapy for heart failure with preserved ejection fraction or reduced ejection fraction in patients with CA. Angiotensin receptor-neprilysin inhibitors, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, MRAs, and sodium-glucose cotransporter-2 inhibitors have not been studied in this population but may be poorly tolerated or even contraindicated due to autonomic dysfunction, oscillating fluid balance, and renal dysfunction. Vasoconstrictors such as midodrine may be needed to manage hypotension, particularly in patients with AL-CA and ATTRv-CA, where autonomic dysfunction can be debilitating. 70 , 71 Since orthostatic hypotension can be challenging to treat, droxidopa may be used as an adjunct to midodrine and compression stockings and was recently approved specifically for management of symptomatic neurogenic orthostatic hypotension. 72 Pyridostigmine, the acetylcholinesterase inhibitor, can also be used but has not been specifically studied in CA. 73 Fludrocortisone should be avoided due to risk of volume retention.

Since CA patients have small stroke volumes, they are dependent on increases in heart rate to augment cardiac output. However, because of extensive fibrosis, CA patients are particularly prone to conduction system disease, syncope, and death. Thus, treatment with atrioventricular nodal blocking agents must be used cautiously since they can contribute to bradyarrhythmias and worsening low-output heart failure. Nondihydropyridine calcium channel blockers are typically contraindicated in CA patients because they bind avidly to amyloid fibrils, have profound negative inotropic effects, and exacerbate bradyarrhythmias. 74

With development of high-degree heart block with or without symptoms, pacemaker implantation is a Class 1-B recommendation. 75 Since high pacing burden has been associated with deleterious remodeling and progressive heart failure symptoms in ATTR-CA, biventricular pacemaker upgrade may be necessary and has been shown to provide functional improvement. 76 The role of implantable cardioverter defibrillators (ICD) is less clear and has been predominantly studied in AL-CA. While appropriate ICD therapies for ventricular arrhythmias are common, particularly in those with less-advanced CA, ICD implantation has not been shown to improve survival. 77 Nevertheless, if a patient with CA has a sudden cardiac arrest with a reasonable survival of greater than 1 year, ICD implantation carries a class I-C recommendation. 75

Due to atrial enlargement from diastolic dysfunction and atrial fibrosis, atrial fibrillation is common and occurs in up to 44% of patients. 78 While there is no clear evidence to support a rate or rhythm control strategy in CA, rhythm control with amiodarone, and less commonly dofetilide or sotalol, is a class IIb-C recommendation due to frequent beta blocker intolerance. Digoxin sensitivity and toxicity was reported over 40 years ago and attributed to potentiated effects from myocardial binding 79 and decreased renal clearance from concomitant renal dysfunction. However, a recent retrospective study of digoxin use in AL-CA suggests possible utility at lower doses and with close serologic monitoring. 80 Cardioversion and ablation can also be considered in select cases and may be most beneficial in earlier disease states, although there is limited data in this population (Class IIb-C recommendation). Since left atrial appendage thrombosis occurs in up to one-third of patients, even in sinus rhythm without a diagnosis of atrial fibrillation, anticoagulation is prescribed for a diagnosis of atrial fibrillation regardless of the CHA2DS2-VASc score and should even be considered in select patients without atrial arrhythmias. 81 , 82 Either warfarin or a direct oral anticoagulant may be safely prescribed. The benefit of atrial appendage occluder device placement in this population has also not been evaluated but can be considered for appropriate patients.

ATTRwt-CA has been reported in up to 16% of patients undergoing transcatheter aortic valve replacement (TAVR). 83 Two recent studies demonstrate safety and similar outcomes for TAVR for ATTRwt-CA with aortic stenosis compared to those with lone aortic stenosis. 84 , 85

Advanced Heart Failure Therapies

Due to the characteristically small and hypertrophied LV with frequent right ventricular involvement, LV assist devices (LVAD) are often not feasible for CA and have been associated with poor outcomes in small studies. 86 Total artificial heart overcomes these barriers to LVAD and was shown to serve as a successful bridge to cardiac transplantation in a small retrospective study. 87

Increasingly, select patients with advanced cardiac disease, with or without renal disease, are considered for heart or combined heart-kidney transplantation, with improving survival rates. 88 , 89 , 90 , 91 Cardiac transplantation provides clinical improvement to facilitate subsequent chemotherapy and autologous stem cell transplantation for those with AL-CA. 92 For patients with ATTRv-CA with neuropathy, heart-liver transplant has historically been performed to prevent progression of debilitating neuropathy but is now superseded by the availability of gene-silencing therapies.

Conclusion

While the prognosis of CA is still poor relative to other forms of cardiomyopathies, the stars have started to align for improvement in CA prognosis with significant advances in diagnostic methods as well as novel and specific disease-modifying therapies. We eagerly await the results of ongoing randomized controlled trials as well as inclusion of this population in future studies to enhance our approach to this disease.

Key Points

While autologous stem cell transplantation was previously favored for up-front treatment of patients with light chain amyloidosis (AL) with acceptable risk, daratumumab in combination with a bortezomib-based chemotherapy regimen recently became the first treatment approved by the US Food and Drug Administration (FDA) for AL amyloidosis as it has demonstrated excellent hematologic and organ response in newly diagnosed AL.

There is hope that daratumumab monotherapy may serve as a safe, tolerable, and efficacious treatment for those with advanced AL cardiac amyloidosis and is currently under investigation.

The transthyretin (TTR) tetramer stabilizer, tafamidis, is the only FDA-approved treatment for transthyretin cardiac amyloidosis (ATTR-CA). However, there are promising novel therapies on the horizon that target pathogenic TTR fibril formation including TTR gene silencers, TTR tetramer stabilizers, oligomer aggregation inhibitors, anti-TTR fiber antibodies, and TTR amyloid degraders (ongoing clinical trials).

For end-stage CA, advanced interventions including heart or heart-kidney transplantation may need to be considered. For patients with hereditary ATTR-CA with neuropathy, heart-liver transplant has been historically performed to prevent progression of debilitating neuropathy but is now superseded by the availability of gene-silencing therapies such as patisiran or inotersen.

Despite the evolution of treatment options, CA management remains complex due to patient frailty and therapeutic side effects in advanced cardiac disease states.

Competing Interests

Jignesh Patel is a consultant for Pfizer, Alnylam, Akcea, and BridgeBio. Lily Stern has no competing interests to declare.

References

1. Adam RD, Coriu D, Jercan A, et al. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Failure. 2021. Aug;8(4):2380-96. doi: 10.1002/ehf2.13443

2. Stern LK, Kittleson MM. Updates in Cardiac Amyloidosis Diagnosis and Treatment. Curr Oncol Rep. 2021. Mar 16;23(4): 47. doi: 10.1007/s11912-021-01028-8

3. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012. Dec 20;30(36):4541-9. doi: 10.1200/JCO.2011.37.7614

4. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020. Dec 3;136(23):2620-2627. doi: 10.1182/blood.2020006913

5. Manwani R, Foard D, Mahmood S, et al. Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis. Haematologica. 2018. Apr;103(4):e165-e168. doi: 10.3324/haematol.2017.178095

6. Sidana S, Milani P, Binder M, et al. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer J. 2020. Apr 14;10(4):41. doi: 10.1038/s41408-020-0306-5

7. Salinaro F, Meier-Ewert HK, Miller EJ, et al. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017. Sep 1;18(9):1057-1064. doi: 10.1093/ehjci/jew298

8. Martinez-Naharro A, Abdel-Gadir A, Treibel TA, et al. Abstract 14407: Regression of Cardiac AL Amyloid by Cardiovascular Magnetic Resonance. Circulation. 2016. Nov 11;134(suppl_1):A14407.

9. Sidiqi MH, Aljama MA, Buadi FK, et al. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. J Clin Oncol. 2018. May 1;36(13):1323-1329. doi: 10.1200/JCO.2017.76.9554

10. Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 2019. Jan 17;133(3):215-223. doi: 10.1182/blood-2018-06-858951

11. Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. J Clin Oncol. 2020. Oct 1;38(28):3252-3260. doi: 10.1200/JCO.20.01285

12. Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021. Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631

13. Genmab.com [Internet]. Copenhagen, Denmark; Genmab; c 2022. Genmab Announces that Janssen has been granted U.S. FDA approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for patients with newly diagnosed light-chain (al) amyloidosis; 2021. Jan 15 [cited 2022 Jan 5]. Available from: https://ir.genmab.com/news-releases/news-release-details/genmab-announces-janssen-has-been-granted-us-fda-approval

14. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis; 2021. Oct 7 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT04131309

15. Manwani R, Mahmood S, Sachchithanantham S, et al. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. Br J Haematol. 2019. Dec;187(5):638-641. doi: 10.1111/bjh.16122

16. Premkumar VJ, Lentzsch S, Pan S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J. 2021. Jan 11;11(1):10. doi: 10.1038/s41408-020-00397-w

17. Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020. Apr 30;135(18):1531-1540. doi: 10.1182/blood.2019004369

18. Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. 2020. Apr 30;135(18):1541-1547. doi: 10.1182/blood.2019004436

19. Warsame R, LaPlant B, Kumar SK, et al. Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer J. 2020. Jan 8;10(1):4. doi: 10.1038/s41408-019-0266-9

20. Dispenzieri A, Dingli D, Kumar SK, et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 2010. Oct;85(10):757-9. doi: 10.1002/ajh.21822

21. Dispenzieri A, Kastritis E, Wechalekar AD, et al. Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician’s Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood. 2019. Nov 13;134(Supplement_1):139. doi: 10.1182/blood-2019-124409

22. Reuters.com [Internet]. Canary Wharf, London: Reuters;c2022. BRIEF: Prothena Discontinues Development of NEOD001 for AL Amyloidosis; 2018. Apr 13 [cited 2022 Jan 5]. Available from: https://www.reuters.com/article/brief-prothena-discontinues-development-idCNASC09WS6

23. Valent J, Silowsky J, Kurman MR, et al. Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study ( NCT04304144 ). Blood. 2020. Dec 6;136(Supplement 1):26-7. doi: 10.1182/blood-2020-139323

24. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine;c 2022. A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis;2021. Dec 7 [cited 2022Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT04512235

25. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis; 2021. Dec 7 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT04504825

26. Ehrnhoefer DE, Bieschke J, Boeddrich A, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008. Jun;15(6):558-66. doi: 10.1038/nsmb.1437

27. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis; 2018. Mar 21 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT01511263

28. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL); 2017. Oct 17 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT02015312

29. Meshitsuka S, Shingaki S, Hotta M, et al. Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis. Int J Hematol. 2017. Mar; 105(3):295-308. doi: 10.1007/s12185-016-2112-1

30. Ward JE, Ren R, Toraldo G, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011. Dec 15;118(25):6610-7. doi: 10.1182/blood-2011-04-351643

31. Diomede L, Rognoni P, Lavatelli F, et al. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood. 2014. Jun 5;123(23):3543-52. doi: 10.1182/blood-2013-10-525634

32. Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 2017. Mar 24;7(3):e546. doi: 10.1038/bcj.2017.26

33. Kumar SK, Dispenzieri A, Lacy MQ, et al. Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation. Blood. 2012;120(21):3138. doi: 10.1182/blood.V120.21.3138.3138

34. Shen KN, Fu WJ, Wu Y, et al. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial. 2022. Jan 4;145(1):8-17. doi: 10.1161/CIRCULATIONAHA.121.055953

35. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy; 2021. Jan 26 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT03474458

36. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018. Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153

37. Solomon SD, Adams D, Kristen A, et al. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation. 2019. Jan 22;139(4):431-443. doi: 10.1161/CIRCULATIONAHA.118.035831

38. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy); 2022. Jan 13 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT03997383

39. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018. Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793

40. Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid. 2020. Mar;27(1):52-58. doi: 10.1080/13506129.2019.1685487

41. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients; 2020. Dec 7 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT03702829

42. Judge DP, Kristen AV, Grogan M, et al. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020. Jun;34(3):357-370. doi: 10.1007/s10557-019-06919-4

43. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; 2022. Jan 13 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT04153149

44. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM); 2022. Jan 11 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT04136171

45. Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021. Aug 5;385(6):493-502. doi: 10.1056/NEJMoa2107454

46. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006. Dec;13(4):236-49. doi: 10.1080/13506120600960882

47. Castaño A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. Nov-Dec 2012;18(6):315-9. doi: 10.1111/j.1751-7133.2012.00303.x

48. Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS. TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis. Circ Heart Fail. 2018. Apr;11(4):e004769. doi: 10.1161/CIRCHEARTFAILURE.117.004769

49. Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda S. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid. 2015;22(2):79-83. doi: 10.3109/13506129.2014.997872

50. Wixner J, Westermark P, Ihse E, Pilebro B, Lundgren HE, Anan I. The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition. Amyloid. 2019;26(sup1):39-40. doi: 10.1080/13506129.2019.1593133

51. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018. Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689

52. Kazi DS, Bellows BK, Baron SJ, et al. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation. 2020. Apr 14;141(15):1214-1224. doi: 10.1161/CIRCULATIONAHA.119.045093

53. Ji AX, Wong PW, Betz A, Sinha U. Abstract 13847: Differential Transthyretin Binding, Kinetic Stability and Additive Ex Vivo Stabilization by AG10 Compared to Tafamidis. Circulation. 2019. Nov 19;140(Suppl_1):A13847-A. doi: 10.1161/circ.140.suppl_1.13847

54. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy; 2021. Dec 30 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT03860935

55. Ferreira N, Cardoso I, Domingues MR, et al. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett. 2009. Nov 19;583(22):3569-76. doi: 10.1016/j.febslet.2009.10.062

56. Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: “in vivo” evidence from FAP mice models. PLoS One. 2012;7(1):e29933. doi: 10.1371/journal.pone.0029933

57. aus dem Siepen F, Bauer R, Aurich M, et al. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des Devel Ther. 2015. Dec 4;9:6319-25. doi: 10.2147/DDDT.S96893

58. aus dem Siepen F, Buss SJ, Andre F, et al. Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clin Res Cardiol. 2015. Aug;104(8):640-7. doi: 10.1007/s00392-015-0826-3

59. Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012. Oct;101(10):805-13. doi: 10.1007/s00392-012-0463-z

60. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010. Jul 30;8:74. doi: 10.1186/1479-5876-8-74

61. Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012. Jun;19 Suppl 1:34-6. doi: 10.3109/13506129.2012.678508

62. Wixner J, Pilebro B, Lundgren HE, Olsson M, Anan I. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis. Amyloid. 2017. Mar;24(sup1):78-79. doi: 10.1080/13506129.2016.1269739

63. Karlstedt E, Jimenez-Zepeda V, Howlett JG, White JA, Fine NM. Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis. J Card Fail. 2019. Mar;25(3):147-153. doi: 10.1016/j.cardfail.2019.01.006

64. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin; 2020. May 14 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT03481972

65. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis; 2020. Aug 20 [cited 2022 Feb 19]. Available from: https://ClinicalTrials.gov/show/NCT03336580

66. Michalon A, Hagenbuch A, Huy C, et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021. May 25;12(1):3142. doi: 10.1038/s41467-021-23274-x

67. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy; 2021. Aug 10 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT04360434

68. Richards DB, Cookson LM, Berges AC, et al. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med. 2015. Sep 17;373(12):1106-14. doi: 10.1056/NEJMoa1504942

69. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022. Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698;2019. Oct 16 [cited 2022 Jan 31]. Available from: https://ClinicalTrials.gov/show/NCT03044353

70. Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. 2015. Jan;168(2):186-206. doi: 10.1111/bjh.13155

71. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020. Jul 7;142(1):e7-e22. doi: 10.1161/CIR.0000000000000792

72. Pérez-Lloret S, Quarracino C, Otero-Losada M, Rascol O. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. Expert Opin Pharmacother. 2019. Apr;20(6):635-645. doi: 10.1080/14656566.2019.1574746

73. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008. Feb 7;358(6):615-24. doi: 10.1056/NEJMcp074189

74. Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985. Jun 1;55(13 Pt 1):1645. doi: 10.1016/0002-9149(85)90995-6

75. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019. Nov;16(11):e301-e372. doi: 10.1016/j.hrthm.2019.05.007

76. Donnellan E, Wazni OM, Saliba WI, et al. Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol. 2019. Nov;30(11):2427-2432. doi: 10.1111/jce.14180

77. Hamon D, Algalarrondo V, Gandjbakhch E, et al. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. Int J Cardiol. 2016. Nov 1;222:562-568. doi: 10.1016/j.ijcard.2016.07.254

78. Sanchis K, Cariou E, Colombat M, et al. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality. Amyloid. 2019. Sep;26(3):128-138. doi: 10.1080/13506129.2019.1620724

79. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981. Jun;63(6):1285-8. doi: 10.1161/01.CIR.63.6.1285

80. Muchtar E, Gertz MA, Kumar SK, et al. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid. 2018. Jun;25(2):86-92. doi: 10.1080/13506129.2018.1449744

81. Donnellan E, Elshazly MB, Vakamudi S, et al. No Association Between CHADS-VASc Score and Left Atrial Appendage Thrombus in Patients With Transthyretin Amyloidosis. JACC Clin Electrophysiol. 2019. Dec;5(12):1473-1474. doi: 10.1016/j.jacep.2019.10.013

82. Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007. Nov 20;116(21):2420-6. doi: 10.1161/CIRCULATIONAHA.107.697763

83. Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017. Oct 7;38(38):2879-2887. doi: 10.1093/eurheartj/ehx350

84. Nitsche C, Scully PR, Patel KP, et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am Coll Cardiol. 2021. Jan 19;77(2):128-139. doi: 10.1016/j.jacc.2020.11.006

85. Scully PR, Patel KP, Treibel TA, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020. Aug 1;41(29):2759-2767. doi: 10.1093/eurheartj/ehaa170

86. Swiecicki PL, Edwards BS, Kushwaha SS, Dispenzieri A, Park SJ, Gertz MA. Left ventricular device implantation for advanced cardiac amyloidosis. J Heart Lung Transplant. 2013. May;32(5):563-8. doi: 10.1016/j.healun.2013.01.987

87. Kittleson MM, Cole RM, Patel J, et al. Mechanical circulatory support for cardiac amyloidosis. Clin Transplant. 2019. Oct;33(10):e13663. doi: 10.1111/ctr.13663

88. Griffin JM, Chiu L, Axsom KM, et al. United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis. Clin Transplant. 2020. Oct;34(10):e14028. doi: 10.1111/ctr.14028

89. Kristen AV, Kreusser MM, Blum P, et al. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. J Heart Lung Transplant. 2018. May;37(5):611-618. doi: 10.1016/j.healun.2017.11.015

90. Vaidya GN, Patel JK, Kittleson M, et al. Intermediate-term outcomes of heart transplantation for cardiac amyloidosis in the current era. Clin Transplant. 2021. Jun;35(6):e14308. doi: 10.1111/ctr.14308

91. Davis MK, Lee PH, Witteles RM. Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant. 2015. May;34(5):658-66. doi: 10.1016/j.healun.2014.09.006

92. Trachtenberg BH, Kamble RT, Rice L, et al. Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis. Am J Transplant. 2019. Oct;19(10):2900-2909. doi: 10.1111/ajt.15487